Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $7.38M rose 40.5% year over year, behind the +75.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +56.0% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $4.47M (-81.0%) for the fiscal year ending Dec 2026, a slowdown from the +107.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.38M+8.9% QoQ
- Last fiscal yearDec 2025
- $23.56M+107.0% YoY
- LTMMar 2026
- $25.68M+75.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 23.56M USD
- Year-over-year change
- +107.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.56M | +107.0% |
| FY2024 | 2024-12-31 | 11.38M | +69.0% |
| FY2023 | 2023-12-31 | 6.73M | +8.4% |
| FY2022 | 2022-12-31 | 6.21M | — |
| FY2021 | 2021-12-31 | 0 | — |
Selling, General & Admin vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 selling, general & admin of $25.68M is the 2nd highest of the 8 companies compared; the peer median is $6.31M.
- Its year-over-year change of +75.9% is the highest of 7, against a peer median of -4.4%.
- Over three fiscal years its annual growth of +56.0% compares with a peer median of -6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $25.68M | +75.9% | +56.0% | — | |
| LTM Mar 2026 | $18.36M | +21.1% | -6.5% | 244.9% | |
| LTM Mar 2026 | $10.32M | -12.0% | -7.1% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $6.31M | — | — | — |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $5.71M | +24.9% | +91.9% | — |
| LTM Mar 2026 | $5.37M | +3.2% | -8.7% | — | |
| LTM Mar 2026 | $2.36M | -26.5% | +12.5% | — | |
| Peer median (excluding IKT) | $6.31M | -4.4% | -6.8% | 140.9% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.1M | 123.44K | 260.5K | 0 | 0 |
| Cost of Revenue | 11.36M | 6.72K | 13.62M | 26.27K | 0 |
| Gross Profit | (8.26M) | 116.72K | (13.36M) | (26.27K) | 0 |
| Gross Margin | -266.4% | 94.6% | -5127.8% | — | — |
| Research & Development | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
| Selling, General & Admin | 0 | 6.21M | 6.73M | 11.38M | 23.56M |
| Operating Expenses | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M |
| Depreciation & Amortization | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K |
| EBITDA | 0 | (18.05M) | (18.85M) | (27.49M) | (53.29M) |
| EBITDA Margin | 0.0% | -14620.4% | -7236.7% | — | — |
| Operating Income | (14.77M) | (18.13M) | (20.09M) | (28.59M) | (51.97M) |
| Operating Margin | -476.2% | -14686.2% | -7712.0% | — | — |
| Interest Income | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M |
| Interest Expense | 19.92K | 74.45K | 0 | 0 | 0 |
| Other Income / Expenses | (19.92K) | 74.45K | 1.06M | 1.07M | 3.72M |
| Income Before Tax | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Pre-Tax Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Net Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (Basic) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| EPS (Diluted) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| Weighted Avg Shares | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
| Weighted Avg Shares (Diluted) | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.